Show simple item record

dc.contributor.authorAdler, Emily K.
dc.contributor.authorCorona, Rosario I.
dc.contributor.authorLee, Janet M.
dc.contributor.authorRodriguez-Malave, Norma
dc.contributor.authorMhawech-Fauceglia, Paulette
dc.contributor.authorSowter, Heidi M.
dc.contributor.authorHazelett, Dennis J.
dc.contributor.authorLawrenson, Kate
dc.contributor.authorGayther, Simon A.
dc.date.accessioned2018-01-25T14:00:27Z
dc.date.available2018-01-25T14:00:27Z
dc.date.issued2017-11-28
dc.identifier.citationAdler, E. K. et al (2017) 'The PAX8 cistrome in epithelial ovarian cancer', Oncotarget, 8 (65).en
dc.identifier.issn19492553
dc.identifier.doi10.18632/oncotarget.22718
dc.identifier.urihttp://hdl.handle.net/10545/622076
dc.description.abstractPAX8 is a lineage-restricted transcription factor that is expressed in epithelial ovarian cancer (EOC) precursor tissues, and in the major EOC histotypes. Frequent overexpression of PAX8 in primary EOCs suggests this factor functions as an oncogene during tumorigenesis, however, the biological role of PAX8 in EOC development is poorly understood. We found that stable knockdown of PAX8 in EOC models significantly reduced cell proliferation and anchorage dependent growth in vitro, and attenuated tumorigenicity in vivo. Chromatin immunoprecipitation followed by next generation sequencing (ChIP-seq) and transcriptional profiling were used to create genome-wide maps of PAX8 binding and putative target genes. PAX8 binding sites were significantly enriched in promoter regions (p < 0.05) and superenhancers (p < 0.05). MEME-ChIP analysis revealed that PAX8 binding sites overlapping superenhancers or enhancers, but not promoters, were enriched for JUND/B and ARNT/AHR motifs. Integrating PAX8 ChIP-seq and gene expression data identified PAX8 target genes through their associations within shared topological association domains. Across two EOC models we identified 62 direct regulatory targets based on PAX8 binding in promoters and 1,330 putative enhancer regulatory targets. SEPW1, which isinvolved inoxidation-reduction,was identified as a PAX8 target gene in both cell line models. While the PAX8 cistrome exhibits a high degree of cell-type specificity, analyses of PAX8 target genes and putative cofactors identified common molecular targets and partners as candidate therapeutic targets for EOC.
dc.description.sponsorshipN/Aen
dc.language.isoenen
dc.publisherImpact Journalsen
dc.relation.urlhttp://www.oncotarget.com/fulltext/22718en
dc.rightsArchived with thanks to Oncotargeten
dc.subjectCanceren
dc.subjectOvarian canceren
dc.titleThe PAX8 cistrome in epithelial ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentUniversity of Southern Californiaen
dc.contributor.departmentCedars-Sinai Medical Centeren
dc.contributor.departmentUniversity of Derbyen
dc.identifier.journalOncotargeten
dcterms.dateAccepted2017-09-30
refterms.dateFOA2019-02-28T16:30:55Z
html.description.abstractPAX8 is a lineage-restricted transcription factor that is expressed in epithelial ovarian cancer (EOC) precursor tissues, and in the major EOC histotypes. Frequent overexpression of PAX8 in primary EOCs suggests this factor functions as an oncogene during tumorigenesis, however, the biological role of PAX8 in EOC development is poorly understood. We found that stable knockdown of PAX8 in EOC models significantly reduced cell proliferation and anchorage dependent growth in vitro, and attenuated tumorigenicity in vivo. Chromatin immunoprecipitation followed by next generation sequencing (ChIP-seq) and transcriptional profiling were used to create genome-wide maps of PAX8 binding and putative target genes. PAX8 binding sites were significantly enriched in promoter regions (p < 0.05) and superenhancers (p < 0.05). MEME-ChIP analysis revealed that PAX8 binding sites overlapping superenhancers or enhancers, but not promoters, were enriched for JUND/B and ARNT/AHR motifs. Integrating PAX8 ChIP-seq and gene expression data identified PAX8 target genes through their associations within shared topological association domains. Across two EOC models we identified 62 direct regulatory targets based on PAX8 binding in promoters and 1,330 putative enhancer regulatory targets. SEPW1, which isinvolved inoxidation-reduction,was identified as a PAX8 target gene in both cell line models. While the PAX8 cistrome exhibits a high degree of cell-type specificity, analyses of PAX8 target genes and putative cofactors identified common molecular targets and partners as candidate therapeutic targets for EOC.


Files in this item

Thumbnail
Name:
Pax8.pdf
Size:
4.736Mb
Format:
PDF
Description:
Publisher's PDF (Open Access CCBY)

This item appears in the following Collection(s)

Show simple item record